Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept for active ulcerative colitis
ACTRN12607000003471Phase 3Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2007
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of abatacept in autoimmune colitis (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Clinical response after induction and maintenance. Planned start Feb 2007; status: not yet recruiting.
02
Drugs
abatacept
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on ACTRN12607000003471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000003471.